Figure 7. Dynamics of changes in the content of lipid derivative of sarcolysin (LDS) in blood components of experimental animals after the addition of Sarcolysin-NP ((100±5) mg/ml of LDS): A – in whole blood (the spread of indications did not exceed 5% and is comparable to the size of the symbol in the figure); B – in plasma and blood form elements (BFE).